Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Nov 18, 2019
American Heart Association Scientific Sessions 2019

November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides”

November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects”

Philadelphia
Nov 25, 2019 4:30 PM EST
Arrowhead Pharmaceuticals 2019 Year End Results
Archived Events
Date Event Details
Feb 7, 2019 4:30 PM EST
Arrowhead Pharmaceuticals 2019 First Quarter Results
Dec 11, 2018 4:30 PM EST
Arrowhead 2018 Fiscal Year End Results
Nov 28, 2018
30th Annual Piper Jaffray Healthcare Conference
New York, NY
November 28, 3:30 p.m. EST – Dr. Anzalone will participate in a fireside chat
Nov 16, 2018
China Nucleic Acids
Guangzhou, China
November 16, 11:20 – Dr. Li will deliver an oral presentation titled, “TRiMTM Platform Based RNAi Therapeutics for AATD and Cardiometabolic Diseases”
Nov 15, 2018
Jefferies 2018 London Healthcare
London
November 15, 2:00 p.m. GMT – Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will deliver a corporate presentation
Nov 13, 2018
30th EORTC-NCI-AACR Symposium
Dublin
November 13, 10:00 a.m. GMT – Dr. Given will deliver a poster presentation titled, “Targeting HIF2α with an RNAi therapeutic for the treatment of clear cell renal cell carcinoma”
Nov 12, 2018
American Heart Association Scientific Sessions 2018
Chicago
November 12, 10:45 a.m. CST – Rui Zhu, Ph.D., Arrowhead’s senior chemist, will deliver an oral presentation titled, “RNA Interference Mediated Apolipoprotein C3 Gene Silencing as a Therapeutic for Hypertriglyceridemia”

November 12, 11:45 a.m. CST – So Wong, Ph.D., Arrowhead’s director of oncology, will deliver an oral presentation titled, “Development of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3 for Treatment of Hyperlipidemia”
Nov 12, 2018
The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

First Results with RNA interference (RNAi) in Chronic Hepatitis B (CHB) Using ARO-HBV

  • Publication Number: LB-25
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 12, 2018 from 8:00 AM to 5:30 PM PT
  • Location: Moscone Center North/South Building, Hall C
  • Authors: Dr. Edward J. Gane, et al.


A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin levels in Normal Adult Volunteers

  • Publication Number: LB-9
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 12, 2018 from 8:00 AM to 5:30 PM PT
  • Location: Moscone Center North/South Building, Hall C
  • Authors: Dr. Christian Schwabe, et al.
Nov 9, 2018
The Search for HBV / HDV Cure: Challenges for Industry
San Francisco
November 9, 11:15 a.m. PST – Dr. Given will deliver an oral presentation titled, “AROHBV1001 Results Update”
Nov 7, 2018
International HBV Cure Workshop 2018
Toronto
November 7, 3:35 p.m. EST – Bruce Given, M.D., Arrowhead’s chief operating officer, will deliver an oral presentation titled, “Clinical update on reducing HBV virus and antigen production using RNAi”